Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Deferasirox (Primary) ; Azacitidine; Colecalciferol
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.